GAO Drug Price Study Finds Fraction Of Products Accounts For Most Increases
Executive Summary
A Government Accountability Office study of drug prices found that a limited number of drugs were responsible for the vast majority of drug price increases between 2000 and 2004
You may also be interested in...
Rx Prices For Medicare, Non-Medicare Groups Show Similar Growth – GAO
Retail prices for drugs frequently used by Medicare enrollees are increasing at a "similar" rate to those used by the non-Medicare population, the Government Accountability Office said
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials